All posts by student

‘Grey’s Anatomy’ Season 13 Finale Says Goodbye to Another Cast Member (SPOILERS) – Variety

SPOILER ALERT:Do notread ahead, if you have not watched the season finale of Greys Anatomy Season 13, which aired onThursday, May 18.

Grey Sloan Memorial said goodbye to one of its own, after a fire rocked the hospital in the Season 13 finale of Greys Anatomy but despite some major foreshadowing, the goodbye was not due to death, unlike most Greys departures.

However, that doesnt mean the exit isnt permanent. The season finale revealed that Jerrika Hintons Dr. Stephanie Edwards is leaving her job and the medical profession entirely. The storyline comes as the actress is exiting the ABC series for a role in Alan Balls new HBO drama, asVariety previously reported.

In Thursday nights episode, after fighting off a rapist and dodging an explosion, Edwards spent the season-ender ignoring her own life-threatening burns to save a little girl which she did, by the way in the process, she realized what she wants out of life: to stop spending all her time in hospitals.

As for Hinton, the actress joined Greys Anatomy in 2012. She expanded her Shondaland relationship last season when she was cast as the lead in the companys comedy pilot Toast, which ultimately did not go to series.

Regarding Hintons exit, in a statement provided toVariety, series creator Shonda Rhimes said: Actors evolve differently and when an actor like Jerrika comes to me and says she wants to try something new creatively, I like to honor that.Jerrika has shared so much of herself with Stephanie and I am incredibly proud of the journey weve taken together. While Im sad to see Stephanie leave Grey Sloan Memorial Hospital, I am excited to see whats next for Jerrika.

Here,Hinton fights back tears as she speaks to Variety about her decision to leave Greys Anatomy, her new HBO series, and why youshouldnt expect to see Edwards back in Seattle any time soon

When did you decide to leave the show?

Shonda and I met almost a year ago now, and we had a very lengthy and gratifying and really splendid conversation about work and creative process. She was immensely supportive of my wishes, and shes really lovely, Shonda. Every private conversation Ive had with her has left with me feeling just heard and seen and respected as a human being and as an artist, and I really appreciate that.

Have we seen the last of Edwards full time, or could we see her come backin a guest role?

I genuinely dont know the answer to that question. I will say, though, that because of the nature of her injuries and because of what she says she wants to experience in her next chapter of life, if we do see her come back through those doors, it will be a long time. I think that she needs to heal. She needs to heal in a variety of ways before that place becomes a viable option again.

Can you pinpoint a favorite moment you had withyour character over the years?

To be honest, that final scene with Jim Pickens [who plays Dr. Webber], that stands out in my memory. That was, for a scene thats so weighty, so heavy, tapping into it was a beautifully straightforward process. Jim is a fantastic scene partner. I always feel very safe with him. And Debbie [Allen, who directed the episode], the way that Debbie really just let us do what we needed to do allowed for all elements to really coalesce. And I havent seen it, [so] I hope that it comes across on screen. But on the day, shooting that was lovely.

Do you have a favorite memory from your time on the show?

I dont know if Im gonna have an opportunity to talk about what I will miss about Stephanie, is that okay? Im gonna miss wow, I didnt expect this. Im feeling emotional now. Need to go grab some Kleenex. I think Im just gonna miss her willingness to go the extra mile for what she believes in. I think its a quality that has been there from day one. I was thinking about this a few weeks ago, and something I remember from back in Season 9 is the way she really rallied Leah and Joe when Shane was going through a hard time. She told them not to give up and that we are all a part of this together. I think that she has such great fortitude and empathy and brilliance, and shes just, I think, for all of the folly of youth that she has, shes such a wonderful person. I was friends with her, and thats a great compliment because I choose friends carefully.

Can you tease anything about your HBO show?

I will say this: Five years of working in Shondaland makes me nervous about teasing things. I think I can, but all of my instincts in my body say, Keep your mouth shut, and Ive gotta work on letting go of that. But its a really wonderful new project. Its a new drama from Alan Ball, who is a phenomenal writer. And I will say that weve already started working on it, and its genuinely been a gratifying, collaborative, generous, and welcoming experience, and I feel so fortunate. I used to say, all the time, that being welcomed into Shondaland felt like winning the lottery, and I still feel that way. And now, moving from there to this, I dont even know whats beyond the lottery.

Even though youre leaving, do you have any intel on Greys Anatomy Season 14?

I literally have zero idea, and I have not asked because I dont work there anymore. When I worked there, I would ask all of those questions, and now that I dont, its a beautiful mystery.

Go here to see the original:
'Grey's Anatomy' Season 13 Finale Says Goodbye to Another Cast Member (SPOILERS) - Variety

Neuroscience Isn’t Just for Scientists: It Solves Real-World Problems … – Big Think

David Eagleman, neuroscientist and host of 'The Brain' on PBS,will speak at the Los Angeles Hope Festival on Sunday, May 21. The event is free but seats are limited. RSVP here.

David Eagleman isn't your garden-variety neuroscientistif there is such a thing. His former neuro lab at Baylor College of Medicine built the technology to help deaf people hear through their skin:

the-secret-lives-of-the-brain-david-eagleman-live-on-big-think-2

"One of the things my lab is doing is building a vibratory vest so that we can feed in sensory information through the skin of your torso rather than through more typical sensory channels. So, for example, were doing this for people who are deaf who want to be able to hear. We set up a microphone on the vest and then the auditory stream is turned into this matrix of vibrations on your skin, and what that does is it feeds in electrical signals into the brain that represent the auditory information.

"And if it sounds crazy that you would ever be able to understand all these signals through your skin, remember that all the auditory system is doing is taking signals and turning them into electrical signals in your brain," he says.

That vest was recently put to a very scholarly use:

Eagleman is best known for his work on sensory substitution, time perception, brain plasticity, synesthesia, and neurolaw, and leverages that research to solve problems in the real worldwhether that's by restoring lost senses, breaking up fights between atheists and believers, or equipping people with tools to have more informed discussions about mass shootings in America. Eagleman points out that in the aftermath of every massacre, people toss around labels like: psycho, sociopath, ADHD, Asperger's.

david-eagleman-on-mass-shootings

"Theres no such thing as a psycho. Thats a meaningless term. What the commentator presumably means is either this person has a psychosis, something like schizophrenia where they have a disorder of cognition, or they mean this person is a psychopath which is not a disorder of cognition. Instead psychopathy is about having no empathy towards other people, not caring at all about other people, seeing other people as objects to get around. Theyre also known as sociopaths. So somebody can have a psychosis or somebody can have a psychopathy or sociopathy, and these are completely different things.

"An understanding of these things in the public dialogue I think would be very important; every time theres a mass shooting there are all sorts of commentators that come out and say things like, 'Well, I heard he had Aspergers' or 'I heard he had ADHD,' or, 'I heard that he wrote dark poetry,' which is, of course, true of most young teenagers. So a better understanding of the vocabulary and what are the issues that come along with these different things is something that I try to disseminate through my work in neuroscience and law."

david-eagleman-can-a-computer-simulate-consciousness

For his talk at theLos Angeles Hope Festival, Eagleman will present ideas from his new neuro lab atStanford University School of Medicine, presenting aframework of the brain as a team of rivals, with different networks driving different behaviors.He'll discuss how a major job of intelligent brains is simulation of the future, and he'll leverage lessons from neuroscience about how we can best steer ourselves into the futurekeeping our behavior consistent with a long-term notion of the self. Tickets are free but seats are limited, so RSVP here.

Below is the full schedule for the Los Angeles Hope Festival.

Excerpt from:
Neuroscience Isn't Just for Scientists: It Solves Real-World Problems ... - Big Think

Global Cancer Immunology and Oncolytic Virology Technologies and Markets Report 2017: Market Should – PR Newswire (press release)

The scope of this report covers current cancer immunotherapy markets for most common cancers. The market segments included in this report are therapeutic monoclonal antibodies (with special focus on checkpoint inhibitors), synthetic interleukins, interferons, and colony-stimulating factors; small kinase inhibitors of cancer-related targets; protective and therapeutic cancer vaccines; and adoptive cell therapies.

This report also covers treatments that are in development for late-stage and early-stage oncolytic viruses. Detailed epidemiological information, discussion of incidence and mortality trends, overview of regulatory landscapes, and analysis of market shares for leading products and companies are also included in this report.

Report Includes

Key Topics Covered:

1: Introduction

- Goals and Objectives - Reasons for Doing This Study - Intended Audience - Scope of The Study - Information Sources for the Technology Assessment - Forecasting Methodology - Geographic Breakdown

2: Summary and Highlights

3: Overview

- Past and Present of Cancer Immunology - What is Cancer? - Treating Cancer - Challenges in Treating Cancer - Cancer and the Immune System - Immunotherapy - Towards Combination Immunotherapy - Focusing on Cell-mediated Adaptive Immunity - Fine Tuning Versus Boosting Cancer Immunity - Early Versus Advanced Stage Cancer Immunotherapy - Personalized Treatment Paradigm - Clinically Significant Types of Cancers - Future of Checkpoint Inhibitors, Cancer Vaccines, and Oncolytic Virology

4: Overview of Cancer Immunotherapy

- Immune System and Immunotherapy - Therapeutic Monoclonal Antibodies - Checkpoint Inhibitors - Biological Response Modifiers - Vaccines - Other - Expanded Information on Selected Product Candidates and Recent Regulatory Applications

5: Oncolytic Virology

6: Major Markets

- Markets for Immunotherapy Products - Markets for Oncolytic Virology Products

7: Company Profiles

- Abbvie Inc. - Adaptimmune - Aduro Biotech - Advantagene - Advaxis Immunotherapies - Amgen - Argos Therapeutics - Ariad Pharmaceuticals - Arog Pharmaceuticals - Aserta Pharmaceuticals - Astellas - Astrazeneca - Avax Technologies - Bavarian Nordic - Bayer Healthcare - Biovex - Boehringer Ingelheim - Boston Biomedical - Bristol-Myers Squibb - Cell Medica - Celldex Therapeutics - Celgene Corp. - Chugai - Cold Genesys - Daiichi Sankyo Co. - Dendreon - Dnatrix - Eisai - Eli Lilly - F Hoffmann La Roche AG - Genelux - Gilead Sciences Inc. - Glaxosmithkline Plc - Hanmi Pharmaceutical - Heat Biologics - Immune Design - Immunocellular Therapeutics Ltd. - Immunomedics Inc. - Immunovaccine Inc. - Immunovative Therapies - Incyte Ciorp. - Inovio Pharmaceuticals Inc. - Janssen Pharmaceuticals - Kadmon Pharmaceuticals Corp. - Kite Pharmaceuticals Inc. - Kyowa Hakko Kirin Co. Ltd. - Ligand Pharmaceuticals Inc. - Lion Biotechnologies - Lokon Pharmaceuticals AB - Medimmune - Merck & Co. - Merck Kgaa - Merck Serono - Medigene AG - Mirati Therapeutics - Multivir Inc. - Newlink Genetics - Northwest Biotherapeutics - Novartis Pharma Services AG - Oncolys Biopharma Inc. - Oncolytics Biotech Inc. - Oncomed Pharmaceuticals Inc. - Oncos Therapeutics Ltd. - Ono Pharmaceutical Co. - Otsuka Pharmaceutical Co., Ltd. - Pfizer Inc. - Plexxikon Inc. - Portola Pharmaceuticals Inc. - Provectus Biopharmacueticals Inc. - Psioxus Therapeutics Ltd. - Sanofi SA - Seattle Genetics - Shanghai Sunway Biotech Co. Ltd. - Shenzhen Sibiono Gentech - Sillajen Biotherapeutics Inc. - Spectrum Pharmaceuticals - Takara Bio Inc. - Takeda Co. Ltd. - Tapimmune Inc. - Targovax - Teva Pharmaceutical Industries Ltd. - TG Therapeutics Inc. - Tracon Pharmaceuticals Inc. - Transgene - VCN Biosciences - Ventirx - Verastem Inc. - Viralytics Ltd. - Virttu Biologics Ltd - Vyriad - Western Oncolytics Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/fpck42/cancer_immunology

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-cancer-immunology-and-oncolytic-virology-technologies-and-markets-report-2017-market-should-reach-965-billion-by-2021-from-730-billion-in-2016-at-a-cagr-of-57---research-and-markets-300458203.html

SOURCE Research and Markets

http://www.researchandmarkets.com

More:
Global Cancer Immunology and Oncolytic Virology Technologies and Markets Report 2017: Market Should - PR Newswire (press release)

CEL-SCI Scientist Presents at AAI – IMMUNOLOGY 2017 Meeting – Business Wire (press release)

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT:CVM) today announced that Daniel Zimmerman, Ph.D., Senior Vice President of Research, Cellular Immunology, presented additional data on its LEAPS rheumatoid arthritis (RA) vaccine candidates CEL-4000 and CEL-2000 at IMMUNOLOGY 2017, the annual meeting of the American Association of Immunologists (AAI), May 12 16 in Washington, D.C.

The title of his poster is Key serum cytokine markers for evaluating the efficacy of vaccine therapy in autoimmune models of rheumatoid arthritis. The abstract can be viewed online or found through the conference website at: http://www.immunology2017.org.

Dr. Zimmerman and the research team concluded that serum concentrations and ratios of key disease-related cytokines can predict therapeutic efficacy in different animal models of RA. The data showed that a reduced RA disease progression was observed in mice treated with LEAPS vaccines and was accompanied by decreased pro-inflammatory cytokines level and increased ratios of anti-inflammatory/regulatory to pro-inflammatory cytokines. Thus, a successful vaccine therapy appears to be associated with a ratio shift in favor of anti-inflammatory/regulatory cytokines. The ability to predict cytokine responses to therapy should allow for better design or choice of the appropriate immunomodulatory LEAPS vaccines and other therapies in RA.

About LEAPS

L.E.A.P.S. (Ligand Epitope Antigen Presentation System) is a CEL-SCI patented platform technology designed to stimulate antigen-specific immune responses in T-cells using synthetic peptides. LEAPS constructs physically link the antigenic peptide with a T-cell binding ligand and are delivered directly to the recipient by injection or through absorption onto mucosal surfaces, potentially enhancing T-cell responses to a particular antigen.

About CEL-SCI

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K and 10-K/A for the year ended September 30, 2016. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

See the original post here:
CEL-SCI Scientist Presents at AAI - IMMUNOLOGY 2017 Meeting - Business Wire (press release)

Global Immunology Partnering 2010 – 2017: Deal trends, players and financials – PR Newswire (press release)

LONDON, May 17, 2017 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/4882472/

Description Global Immunology Partnering 2010 to 2017 provides the full collection of Immunology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Immunology partnering deals Financial deal terms for headline, upfront and royalty by stage of development Immunology partnering agreement structure Immunology partnering contract documents Top Immunology deals by value Most active Immunology dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Immunology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Immunology deals.

The report presents financial deal terms values for Immunology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Immunology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Immunology dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Immunology deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Immunology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Immunology deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Immunology partnering deals by specific Immunology target announced since 2010. The chapter is organized by specific Immunology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Immunology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Immunology partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Immunology technologies and products.

Report scope Global Immunology Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Immunology trends and structure of deals entered into by leading companies worldwide.

Global Immunology Partnering 2010 to 2017 includes: - Trends in Immunology dealmaking in the biopharma industry since 2010 - Analysis of Immunology deal structure - Access to headline, upfront, milestone and royalty data - Access to hundreds of Immunology deal contract documents - Comprehensive access to over 3500 Immunology deal records - The leading Immunology deals by value since 2010 - Most active Immunology dealmakers since 2010

The report includes deals for the following indications: AIDS, Allergy, Anaphylactic shock, Graft versus host disease, Inflammation, Other autoimmune, Scleroderma, Systemic lupus erythematosus, plus other immunology indications.

In Global Immunology Partnering 2010 to 2017, available deals and contracts are listed by: - Headline value - Upfront payment value - Royalty rate value - Stage of development at signing - Deal component type - Technology type - Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Immunology Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 700 immunology deals.

Analyzing actual contract agreements allows assessment of the following: - What are the precise rights granted or optioned? - What is actually granted by the agreement to the partner company? - What exclusivity is granted? - What is the payment structure for the deal? - How are the sales and payments audited? - What is the deal term? - How are the key terms of the agreement defined? - How are IPRs handled and owned? - Who is responsible for commercialization? - Who is responsible for development, supply, and manufacture? - How is confidentiality and publication managed? - How are disputes to be resolved? - Under what conditions can the deal be terminated? - What happens when there is a change of ownership? - What sublicensing and subcontracting provisions have been agreed? - Which boilerplate clauses does the company insist upon? - Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? - Which jurisdiction does the company insist upon for agreement law?

Benefits Global Immunology Partnering 2010 to 2017 provides the reader with the following key benefits: - In-depth understanding of Immunology deal trends since 2010 - Access Immunology deal headline, upfront, milestone and royalty data - Research hundreds of actual contracts between Immunology partner companies - Comprehensive access to over 750 links to actual Immunology deals entered into by the world's biopharma companies - Indepth review of Immunology deals entered into by the top 25 most active dealmakers - Benchmark the key deal terms companies have agreed in previous deals - Identify key terms under which companies partner Immunology opportunities Download the full report: https://www.reportbuyer.com/product/4882472/

About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: http://www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-immunology-partnering-2010---2017-deal-trends-players-and-financials-300459424.html

SOURCE ReportBuyer

http://www.reportbuyer.com

Excerpt from:
Global Immunology Partnering 2010 - 2017: Deal trends, players and financials - PR Newswire (press release)

How Understanding Human Behavior Can Open Up New Design Opportunities – Core77.com

There are few people in the design world more familiar with field research, and the extensive travel that goes with it, than Jan Chipchase. On May 6th, Jan launched what has turned out to be a very successful Kickstarter campaign to publish his most recent book,The Field Study Handbook. There's still time to pre-order a copy of what looks to be a fascinating read, even if field research in the Hindu Kush is not on your immediate list of things to do.

Jan is a researcher, writer and photographer whose work focuses on the intersection of design, tech, human behavior and culture. Over the years, he's led research teams investigating both mainstream and emerging markets for Nokia and frog design. In 2014, he founded Studio D, a research, design and innovation consultancy, and later used his extensive travel experiences to create an ultra-light luggage brand, SDR Traveller.

I had a chance to catch up with Jan to talk about the book launch and other recent adventures and activities, as well as ask for some travel advice.

This interview has been edited for length and clarity.

Core77: In addition to Studio D and SDR Traveller, I see also that you run as service called The Fixer List. What is that all about? It seems mysterious.

JC: Fixers are a staple of field research, at least with the way I run projects. Each project includes a local crew that is usually led by someone I call a "fixer". They come from very diverse backgrounds, often speak multiple languages, have a very good sense of their home locale and know how to hustle. Over the years, many of these connections have stayed in touch.

The Fixer List is the Studio D list of unusual talent that we can draw on to run projects around the world. We receive a lot of applicants.

You spend a large percentage of your time on the road, traveling extensively across the world. What are some notable recent field trips you've taken?

JC: Saudi Arabia was interesting and challenging. We were there gathering insights to understand the value proposition of a new brand offering. The new service, Jawwy, went live last year. The team had to achieve a high level of understanding of the local culture and how it maps to a mobile service, in only a month. Many foreigners would struggle to achieve this level of understanding in a lifetime. All credit to our local team of ten people for getting us that far.

Last year I took a tough, 7,000km overland expedition through Kyrgyzstan, Tajikistan's GBAO region and China's western provinces. The trip was full of remote communities, dubious border crossings, permeable borders and lots of checkpoints. I learned a lot on that trip and wrote up my thoughts in a Medium post called 61 Glimpses of the Future.

Another interesting trip involved training a client's team on field research methods, including setting up a mountain retreat at the edge of the Tibetan Plateau to process the data. On every project we get to ask "Where is the best place to figure out x?" and "Where do we want to be today?"

Naturally, the Kickstarter includes expeditions as rewards, if you're up for A Short Walk in the Hindu Kush.

In the Kickstarter video, you mention that the book is part of a mission to reframe the relationship between those that make things and those that consume them. Can you talk about this a bit?

JC: Increasingly, the impetus for creating new products will be based on the data analytics of mass consumption, feedback on marketing strategies, and optimized value engineering. The product creators are removed from their audience by several steps, and it is easy to lose touch with that actual audience. The ability to gather an over abundance of data only compounds the problem. As more data comes on stream, revealing what people are doing and how, there is a growing danger of people being treated as little more than lines in a database, stripped of personality and context, there solely to be mined and monetized.

Field research is defined by closeness and empathy. You get close to those you are studying, and in doing so, develop a deeper empathy for their lives and ways of living. You then take that empathy andin the best casesreflect it back on them through your work. In the right hands, it generates very rich, and very nuanced, data that is capable of answering why people do what they do. Understanding the motivations behind people's actions can lead to very different outcomes, if all you knew before was what people did and how.

I try (and usually fail) to not pack too much when I travel. As a seasoned traveller what are some of your suggestions and tips for packing?

JC: Everybody over packs. It's human nature! By packing less, you're actually more flexible and better able to alter your planned itinerary to react to interesting opportunities. My own preference is to use hand-held luggage (no wheels allowed!), make sure the bag can fit under an economy-class seat or a business class foot-well, and even with that small size, still leave room in your bag for things you might pick up along the way. I wrote about how the psychology of packing impacts the experience of the journey, and it still holds true.

Check out the book, and other rewards available for pre-order on the Kickstarter page forThe Field Study Handbook.

Article illustration, and book illustrations, by Lee Phillips (@leejohnphillips)

Join over 300,000 designers who stay up-to-date with the Core77 newsletter...

Subscribe

Test it out; it only takes a single click to unsubscribe

Stuart Constantine is a co-founder of Core77. He lives in Connecticut with his wife, three children, a collection of bikes and guitars.

Read more here:
How Understanding Human Behavior Can Open Up New Design Opportunities - Core77.com

Turns Out Nazis Have Some Pretty Wrong Views About Genetics – New York Magazine

Photo: Stefano Bianchetti/Getty Images

Most people tend to have a certain idea about their heritage: that they simply are, well, whatever they are. Scottish or German or Nigerian or whatever else. Maybe theres some other stuff mixed in there, sure, but most people have a sense that theyre from one particular place, and thats where their culture and maybe some of their values originates.

Naturally, DNA tells a more complicated story, and a new article in Science by Ann Gibbons very usefully punctures a bunch of myths, some of them pretty harmful, about human ancestry. The vast majority of us are mutts, it turns out, and oftentimes the genetic heritage we think we have bears little resemblance to whats actually hiding in our chromosomes.

Gibbons starts the article by quoting a German neo-Nazi, doing what neo-Nazis tend to do, expressing alarm about the arrival of Syrian refugees and the prospect of them sullying his precious German genetic heritage.

From there she swiftly moves to the main point of the article:

Using revolutionary new methods to analyze DNA and the isotopes found in bones and teeth, scientists are exposing the tangled roots of peoples around the world, as varied as Germans, ancient Philistines, and Kashmiris. Few of us are actually the direct descendants of the ancient skeletons found in our backyards or historic homelands. Only a handful of groups today, such as Australian Aborigines, have deep bloodlines untainted by mixing with immigrants.

That aforementioned notion of German purity, to take one example, comes from a Nazi mangling of an already somewhat thinly sourced story about a Germanic fighter named Arminius who supposedly led a rebellion against the Romans 2,000 years ago the Nazis portrayed him as a blond-haired member of a supposed master race.

Now, it shouldnt be surprising that Nazis dont have a particularly sophisticated grip on genetics. But this article is still an interesting, comprehensive look at where researchers are in their quest to understand humanitys genetic legacy. And the short, also-unsurprising answer is: Weve moved around a lot and mixed it up a lot.

Gibbonss piece also usefully complicates the notion of genetic superiority, highlighting just how historically contingent this idea is. For example, she writes of two different groups that collided at one point and produced offspring: The unions between the Yamnaya and the descendants of Anatolian farmers catalyzed the creation of the famous Corded Ware culture, known for its distinctive pottery impressed with cordlike patterns According to DNA analysis, those people may have inherited Yamnaya genes that made them taller; they may also have had a then-rare mutation that enabled them to digest lactose in milk, which quickly spread It was a winning combination. The Corded Ware people had many offspring who spread rapidly across Europe. Today, of course, very few people are aware of the Corded Ware culture a group that was very much, for random genetic reasons, in the right place at the right time.

For most of human history, humans havent been great at recording history accurately, so along the way many cultures have developed myths about their lineage, about who was where, when. A lot of the time, the straightforward stories people tell to be proud of themselves and their ancestors are oversimplifications, at best. In the worst cases, these myths lead to ideologies like nationalism.

Its important to understand the appeal and functional role of bloodline myths, of course: This group could sully our bloodlines packs a bit more of a visceral punch than I am nervous this new group will cause the neighborhood to change. Because people dont tend to really understand genetics, and because the subject efficiently taps into many peoples most intimate feelings about disgust and purity, such talk can be a useful way to rile people up, almost always for the worse. Which is why its important to understand just how superficial it really is.

The psychology of how we choose who to leave out.

Research suggests that sexism in hiring cant explain the entire gender gap in leadership positions theres other stuff going on, too.

Just about everyone, everywhere, is a complicated mutt, and stories about pure bloodlines are almost always false.

Labels like organic and natural are impossibly vague and often misleading.

Most adults can do a decent job of understanding other peoples internal mental states. Not the leader of the free world.

Or its about to be, at least. Thats just the life cycle of any fad.

It might seem counterintuitive to advertise a place for injection-drug users to shoot up, but theres smart public-health reasoning behind the idea.

Not exactly, but theres some merit to the myth.

Time to find another hangover remedy.

A realization about monogamy that should make anyone getting married feel a little more hopeful.

Its a mixed bag.

The science behind a common-sense piece of advice.

Giving your mind time to wander is a key part of creativity.

Theres a bit of dissent within the American Psychological Association about the role of video games in contributing to violence.

A new TEDx video sums up the research of Bella DePaulo, a social psychologist who has been chipping away at the many myths surrounding marriage.

No matter how long they live in a loud urban environment.

The WHO and the CDC offer different recommendations for proper handwashing technique. Which is right?

Drinking with the author of Cork Dork, a new book about the obsessive world of wine.

A new study explains.

During the current fixation on the intersection of design and psychology, its worth remembering what workers are going through at the moment.

Here is the original post:
Turns Out Nazis Have Some Pretty Wrong Views About Genetics - New York Magazine

The genetic architecture of risk for autism spectrum disorder – Medical Xpress

May 16, 2017 by Karen Zusi Credit : Susanna M. Hamilton, Broad Communications

A new study of inherited genetic risk indicates that common genetic variations throughout the genome act in addition to rare, deleterious mutations in autism-associated genes to create risk for autism.

Studies of genetic risk for developing autism spectrum disorder (ASD) often compare DNA from those diagnosed with autism to that of neurotypical controls, but these approaches can be confounded by external factors. To get a clearer look at the genetic underpinnings of autism risk, a team led by researchers from the Broad Institute's Stanley Center for Psychiatric Research and the Analytic and Translational Genetics Unit at Massachusetts General Hospital and Harvard Medical School took a new approach, published in Nature Genetics, comparing genetic influences within families in which a child has been diagnosed with autism.

In the human genome, common genetic variations can each contribute a small level of risk for developing a given disorder. These variants can be aggregated to create a "polygenic risk score," which represents part of an individual's overall disorder risk.

In this study, Elise Robinson, an associated scientist at Broad and assistant professor of epidemiology at the Harvard T.H. Chan School of Public Health, first author Daniel Weiner, a scientist in Robinson's lab, and colleagues calculated polygenic risk scores for developing autism in members of 6,454 families with one or more children diagnosed with ASD. The risk scores were based on the participants' individual genotypes compared against data from genome-wide association studies.

On average, children's genetic risk scores for any phenotype equal an average of their parents' scores. However, the team discovered that children with ASD have a higher risk score on average for developing ASDmeaning that more of the contributing common variants from the parents have been inherited together, versus what would be expected if the risk score was an average of the parents'. Children with ASD in the study were also likely to have independently over-inherited their parents' polygenic risk for developing schizophrenia, as well as polygenic influences associated with more years of education (which are strongly correlated with the polygenic influences on IQ score).

The independent inheritance of these influences may help to explain the different ways that autism can manifest. For example, higher polygenic risk for schizophrenia was associated with lower IQ , whereas higher polygenic scores for years of education were associated with higher IQ, in children with ASD.

The team also found that risk for developing ASD is increased beyond the common polygenic risk score if a rare, harmful mutation, newly arising in the child, occurs in an autism-associated gene. In children with ASD, these rare variants are associated with more severe neurodevelopmental impacts, such as intellectual disability, seizures, and motor function delay.

The study results point to multiple types of genetic risk for ASD, highlighting the need for a better understanding of the behavioral and cognitive traits associated with autism in order to eventually develop models or therapies. Using genetic data from parents and their children to dissect the roots of a disorder also eliminates many potential confounding factors, and the research team noted the utility of this analytic method for studying other types of polygenic risk.

Explore further: Autism genes are in all of us, new research reveals

More information: Daniel J Weiner et al. Polygenic transmission disequilibrium confirms that common and rare variation act additively to create risk for autism spectrum disorders, Nature Genetics (2017). DOI: 10.1038/ng.3863

New light has been shed on the genetic relationship between autistic spectrum disorders (ASD) and ASD-related traits in the wider population, by a team of international researchers including academics from the University ...

Scientists from King's College London have used a new genetic scoring technique to predict academic achievement from DNA alone. This is the strongest prediction from DNA of a behavioural measure to date.

(HealthDay)For women affected by familial breast cancer, a polygenic risk score based on 22 genomic variants can identify women at high-risk of breast cancer, according to a study published in the Dec. 10 issue of the ...

The causes of autism and autism spectrum disorder (ASD) are complex, and contain elements of both nature (genes) and the environment. New research published in BioMed Central's open access journal Molecular Autism shows that ...

Are deficits in attention limited to those with attention-deficit/hyperactivity disorder (ADHD) or is there a spectrum of attention function in the general population? The answer to this question has implications for psychiatric ...

Stop-and-go traffic is typically a source of frustration, an unneccesary hold-up on the path from point A to point B. But when it comes to the molecular machinery that copies our DNA into RNA, a stop right at the beginning ...

A new study of inherited genetic risk indicates that common genetic variations throughout the genome act in addition to rare, deleterious mutations in autism-associated genes to create risk for autism.

Sharing medical information, including genomic data, has the potential to benefit public health. However, companies that generate that information have a legal right to protect it as a trade secret. Legal and ethical conflict ...

A landmark study led by UNC School of Medicine researchers has identified the first genetic locus for anorexia nervosa and has revealed that there may also be metabolic underpinnings to this potentially deadly illness.

When a group of researchers in the Undiagnosed Disease Network at Baylor College of Medicine realized they were spending days combing through databases searching for information regarding gene variants, they decided to do ...

A new Northwestern Medicine study, published in Genes and Development, has identified two DNA elements crucial to the activation of a set of genes that drive the early development of embryos, and which also play an important ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read the original here:
The genetic architecture of risk for autism spectrum disorder - Medical Xpress

U. biochemistry professor wins Rosenblatt Prize – Deseret News

David Titensor, University of Utah

Wesley I. Sundquist, distinguished professor of biochemistry at the University of Utah, has won the Rosenblatt Prize for Excellence, the U.s most prestigious faculty award.

SALT LAKE CITY Wesley I. Sundquist, distinguished professor of biochemistry at the University of Utah, has won the Rosenblatt Prize for Excellence, the U.s most prestigious faculty award.

The $40,000 gift is presented annually to a faculty member who displays excellence in teaching, research and administrative efforts.

The Rosenblatt Prize Committee, a group of faculty members, recommends candidates for the award. U. President David Pershing made the final selection.

Dr. Sundquists discoveries have enriched the field of biochemistry and hold enormous promise for improving human health, Pershing said in a statement. His dedication as a teacher and mentor ensures that his influence will be felt for generations to come. The University of Utah is fortunate to have a scientist and educator of his caliber, and it is a pleasure to honor him with the institutions most distinguished faculty award.

Sundquist holds a doctorate in chemistry from the Massachusetts Institute of Technology, was a postdoctoral fellow at the MRC Laboratory of Molecular Biology in Cambridge, England, and began his career at the U. in 1992 as an assistant professor in the biochemistry department. He became the Samuels Presidential Chaired Professor in 2015 and a distinguished professor in 2017.

Sundquist is chairman emeritus of the U. School of Medicine's executive committee and former chairman of the Benning Society. He has also served as co-chairman for the biochemistry department with Chris Hill since 2009.

Sundquist is internationally recognized for his research discoveries in HIV replication and fundamental processes in cell biology. His work has transformed the understanding of the architecture, assembly and budding of HIV, and his research on viral structures is leading to new strategies for HIV therapeutics that have transformative potential for human health.

More here:
U. biochemistry professor wins Rosenblatt Prize - Deseret News

Is the Hospital Going to Explode on Grey’s Anatomy? – POPSUGAR

411 Shares

Chat with us on Facebook Messenger. Learn what's trending across POPSUGAR.

Not to alarm you or anything, but we may have blown this year's Grey's Anatomy finale wide open. As you might recall, the penultimate episode of the season comes to an explosive end when Stephanie inadvertently causes an oxygen tank to explode. You know, after setting that crazy stalker rapist on fire. While this has us wondering if Stephanie is dead or alive, it could have even graver implications when it comes to the season finale. Back in March, we already got a few details about the episode. Jessica Capshaw told us that it would be "quite explosive," while Chandra Wilson said it would be "big and loud and strong." Are you sensing where we're going with this?

We have a feeling the whole hospital is going to explode. It's not unreasonable. After all, there's already been a huge explosion in one wing. The finale could show the entire cast in crisis, trying desperately to put out fires and save lives. But what if they can't control the fire in time? The episode is called "Ring of Fire." What if the fire overwhelms the hospital while all the other doctors are inside? What if, in the final moments, Grey Sloan Hospital explodes? If you have any doubts, just know this: Shonda Rhimes came up with the idea way back in 2009.

what if at the end of this season of Grey's Anatomy, the hospital just exploded into flames and we don't know who lives or who dies?

shonda rhimes (@shondarhimes) March 9, 2009

See you on Thursday. We'll bring tissues.

Fall TV

Your Guide to Fall's Primetime TV Schedules

by Maggie Pehanick 13 hours ago

Beauty Tips

The $4 and $5 Concealers That Make My Stubborn Under-Eye Circles Disappear

by Sarah Siegel 2 hours ago

Camilla Luddington

Grey's Anatomy's Camilla Luddington Welcomes a Baby Girl

by Kelsie Gibson 4/11

Entertainment Video

Meet Dr. Kari, the Woman Behind Hollywoods Goddess Locs

by M'Ballu Tejan-Sie 1 week ago

Jensen Ackles

Jared Padalecki and Jensen Ackles Have So Much in Common, They're Like Real Brothers

by Shannon Vestal Robson 3 hours ago

Food News

7 Things You Never Knew About Olive Garden, Straight From an Employee

by Erin Cullum 4 hours ago

Grey's Anatomy

5 Connections Between 13 Reasons Why and Grey's Anatomy

by Kelsie Gibson 4/16

Rachel Lindsay

The Bachelorette: Meet the Diverse Group of Men Competing For Rachel's Heart

by Maggie Pehanick 7 hours ago

Heels

Get Your Shine On! These 18 Shoes Have Serious Star Power

by Macy Cate Williams 4 hours ago

Grey's Anatomy

Grey's Anatomy Was Almost Called Something Else and It Was Terrible

by Maggie Pehanick 2 weeks ago

Tim Allen

Even If You Didn't Watch Last Man Standing, You Need to Hear This Drama

by Maggie Pehanick 23 hours ago

Food Video

Let's Get Down to Business to Cook Mulan's Mu Shu Pork

by Megan Lutz 4 days ago

See more here:
Is the Hospital Going to Explode on Grey's Anatomy? - POPSUGAR